Barnabei Agnese, Strigari Lidia, Marchetti Paolo, Sini Valentina, De Vecchis Liana, Corsello Salvatore Maria, Torino Francesco
Endocrinology Unit, "Regina Elena" National Cancer Institute of Rome, Rome, Italy.
Laboratory of Medical Physics and Expert Systems, "Regina Elena" National Cancer Institute of Rome, Rome, Italy.
Oncologist. 2015 Oct;20(10):1111-8. doi: 10.1634/theoncologist.2015-0183. Epub 2015 Sep 4.
The assessment of ovarian reserve in premenopausal women requiring anticancer gonadotoxic therapy can help clinicians address some challenging issues, including the probability of future pregnancies after the end of treatment. Anti-Müllerian hormone (AMH) and age can reliably estimate ovarian reserve. A limited number of studies have evaluated AMH and age as predictors of residual ovarian reserve following cytotoxic chemotherapy in breast cancer patients.
To conduct a meta-analysis of published data on this topic, we searched the medical literature using the key MeSH terms "amenorrhea/chemically induced," "ovarian reserve," "anti-Mullerian hormone/blood," and "breast neoplasms/drug therapy." Preferred Reporting Items for Systematic Reviews and Meta-Analyses statements guided the search strategy. U.K. National Health Service guidelines were used in abstracting data and assessing data quality and validity. Area under the receiver operating characteristic curve (ROC/AUC) analysis was used to evaluate the predictive utility of baseline AMH and age model.
The meta-analysis of data pooled from the selected studies showed that both age and serum AMH are reliable predictors of post-treatment ovarian activity in breast cancer patients. Importantly, ROC/AUC analysis indicated AMH was a more reliable predictor of post-treatment ovarian activity in patients aged younger than 40 years (0.753; 95% confidence interval [CI]: 0.602-0.904) compared with those older than 40 years (0.678; 95% CI: 0.491-0.866). We generated a nomogram describing the correlations among age, pretreatment AMH serum levels, and ovarian activity at 1 year from the end of chemotherapy.
After the ongoing validation process, the proposed nomogram may help clinicians discern premenopausal women requiring cytotoxic chemotherapy who should be considered high priority for fertility preservation counseling and procedures.
对于需要接受抗癌性腺毒性治疗的绝经前女性,评估其卵巢储备有助于临床医生解决一些具有挑战性的问题,包括治疗结束后未来怀孕的可能性。抗苗勒管激素(AMH)和年龄能够可靠地评估卵巢储备。仅有少数研究评估了AMH和年龄作为乳腺癌患者细胞毒性化疗后残余卵巢储备的预测指标。
为了对该主题的已发表数据进行荟萃分析,我们使用医学主题词“闭经/化学诱导”、“卵巢储备”、“抗苗勒管激素/血液”和“乳腺肿瘤/药物治疗”检索了医学文献。系统评价和荟萃分析的首选报告项目声明指导了检索策略。英国国家医疗服务体系指南用于提取数据并评估数据质量和有效性。采用受试者工作特征曲线下面积(ROC/AUC)分析来评估基线AMH和年龄模型的预测效用。
对所选研究汇总数据的荟萃分析表明,年龄和血清AMH都是乳腺癌患者治疗后卵巢活性的可靠预测指标。重要的是,ROC/AUC分析表明,与40岁以上患者(0.678;95%置信区间[CI]:0.491-0.866)相比,AMH是40岁以下患者治疗后卵巢活性更可靠的预测指标(0.753;95%CI:0.602-0.904)。我们生成了一个列线图,描述了年龄、化疗前AMH血清水平与化疗结束后1年卵巢活性之间的相关性。
在正在进行的验证过程之后,所提出的列线图可能有助于临床医生识别需要接受细胞毒性化疗的绝经前女性,这些女性应被视为生育力保存咨询和程序的高度优先对象。